Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis Denosumab RANKL RANK AMG 162 joint damage Developmental Phase III
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 679
Healthy volunteers: no

Brief summary:
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.

Detailed description:
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or every 3 months for 12 months to rheumatoid arthritis participants.

Arms:
arm 1: denosumab administered subcutaneously every 6 months arm 2: denosumab administered subcutaneously every 3 months arm 3: placebo administered subcutaneously to match denosumab

Interventions: intervention 1: denosumab intervention 2: placebo
Intervention descriptions: intervention 1: denosumab administered subcutaneously intervention 2: placebo administered subcutaneously to match denosumab

Protocol document: